The consensus price target hints at a 29.1% upside potential for Alkermes (ALKS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Abacus FCF Advisors LLC bought a new position in shares of Alkermes plc (NASDAQ: ALKS) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 219,495 shares of the company's stock, valued at approximately $6,141,000. Abacus FCF Advisors LLC owned 0.13%
Avoro Capital Advisors LLC reduced its holdings in Alkermes plc (NASDAQ: ALKS) by 22.8% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,240,000 shares of the company's stock after selling 660,000 shares during the period. Alkermes comprises 0.9% of Avoro Capital
ALKS, BBSI and CBZ have been added to the Zacks Rank #5 (Strong Sell) List on March 11th, 2026.
ALKS beats Q4 earnings and revenue estimates, but shares fall 7%. The company announces a CEO transition plan.
While the top- and bottom-line numbers for Alkermes (ALKS) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Alkermes (ALKS) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $1.04 per share a year ago.
Alkermes plc (ALKS) Q4 2025 Earnings Call Transcript
Here is how Alkermes (ALKS) and American Well Corporation (AMWL) have performed compared to their sector so far this year.
Alkermes (ALKS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here is how Alkermes (ALKS) and CASI Pharmaceuticals Inc. (CASI) have performed compared to their sector so far this year.
Here is how Alkermes (ALKS) and CASI Pharmaceuticals Inc. (CASI) have performed compared to their sector so far this year.